News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Setrusumab receives Breakthrough Therapy designation from the FDACash of $80.5 million as of September 30, 2024, expected to fund operations into ...

The shopping team at Woman's World spends countless hours learning about the latest and greatest offerings from brands you know. But the team spends even more time getting to know the brands you don't ...

Choose your doctor wisely. If you believe your oncologist does not involve you in your treatment plan or is not empathetic, ...

Our NICE Advice service will guide you there. Get reliable scientific advice and NHS insights, direct from NICE. We support companies seeking nationwide adoption of the best treatments and care. Our ...

Systemic treatments are designed to target cancer cells throughout the body. The most common systemic therapies for stage 4 breast cancer include: Hormone Therapy: Hormone therapy is effective for ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...

A study conducted in Denmark examined the relationship between sex hormone levels and major depressive disorder (MDD) in ...

1. 内分泌药物治疗时代 他莫昔芬（tamoxifen，TAM）、芳香化酶抑制剂（aromatase inhibitors，AI）、氟维司群（fulvestrant）是乳腺癌内分泌治疗的基本药物。 1977年，抗雌激素药物他莫昔芬在美国的获批拉开了内分泌治疗的序幕，标志着乳腺癌正式进入内分泌药物治疗 ...